Urogen Pharma $URGN Stock: Privium Fund Management B.V. Decreases Position

Privium Fund Management B.V. decreased its position in Urogen Pharma (NASDAQ:URGN) by 48.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 107,915 shares of the company’s stock after selling 102,085 shares during the period. Urogen Pharma comprises approximately 0.8% of Privium Fund Management B.V.’s portfolio, making the stock its 26th biggest holding. Privium Fund Management B.V. owned 0.22% of Urogen Pharma worth $4,385,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Sterling Capital Management LLC raised its stake in shares of Urogen Pharma by 442.1% during the 3rd quarter. Sterling Capital Management LLC now owns 1,339 shares of the company’s stock worth $54,000 after buying an additional 1,092 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma in the 2nd quarter valued at about $66,000. Quantbot Technologies LP acquired a new stake in Urogen Pharma in the 2nd quarter valued at about $78,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Urogen Pharma in the 3rd quarter valued at about $101,000. Finally, State of Wyoming increased its holdings in Urogen Pharma by 773.4% during the 3rd quarter. State of Wyoming now owns 4,629 shares of the company’s stock valued at $188,000 after acquiring an additional 4,099 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma News Roundup

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.77 from a loss of $0.83, and lifted its Q4 2026 and Q1 2027 forecasts to $0.02 per share. The firm maintained its Buy rating and $75 target. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Sell-side brokerages collectively rate URGN “Moderate Buy,” though that consensus provides limited near-term direction. Urogen Pharma Stock Now Rated Moderate Buy
• Negative Sentiment: HC Wainwright cut its FY2027 EPS forecast to $0.59 from $1.05, lowering estimates for Q2, Q3 and Q4 2027 as well. The reductions suggest a less favorable profit outlook, despite the firm’s unchanged Buy rating and target.
• Negative Sentiment: The latest quarterly results missed expectations: UroGen reported a $0.03-per-share loss versus consensus earnings of $0.11, while revenue of $89 million was slightly below estimates. Reports said shares fell sharply after the results and slipped below their 200-day moving average. Shares Break Below Two Hundred Day Moving Average on Disappointing Earnings

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,202 shares of Urogen Pharma stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the sale, the chief financial officer directly owned 4,561 shares of the company’s stock, valued at approximately $167,343.09. The trade was a 32.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the transaction, the general counsel owned 53,141 shares of the company’s stock, valued at $2,260,618.14. This trade represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 65,269 shares of company stock worth $3,037,646 over the last ninety days. 4.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. UBS Group restated an “outperform” rating on shares of Urogen Pharma in a research report on Thursday. Guggenheim lowered their price target on shares of Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday. Jefferies Financial Group reissued a “buy” rating and set a $56.00 price objective on shares of Urogen Pharma in a research note on Thursday, September 10th. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. Finally, Oppenheimer set a $60.00 target price on Urogen Pharma in a research note on Thursday. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.38.

Urogen Pharma Stock Performance

Urogen Pharma stock traded down $0.98 during midday trading on Friday, reaching $24.75. 1,758,050 shares of the company were exchanged, compared to its average volume of 1,169,568. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -18.75 and a beta of 1.68. The firm’s 50-day simple moving average is $38.78 and its 200-day simple moving average is $31.53. Urogen Pharma has a 1 year low of $16.50 and a 1 year high of $50.81.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to analysts’ expectations of $89.92 million. On average, analysts forecast that Urogen Pharma will post -0.20 EPS for the current fiscal year.

About Urogen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.